Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin

References

• Ferrannini E, Gastaldelli A, Miyazaki Y, et al. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90:493–500.
   PubMed Web of Science ®Google Scholar
• Khunti K, Davies M, Majeed A, et al. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with Type 1 and Type 2 diabetes: a cohort study. Diabetes Care. 2015;38:316–322.
   PubMed Web of Science ®Google Scholar
• UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–1147.
   PubMed Web of Science ®Google Scholar
• McNay EC, Teske JA, Kotz CM, et al. Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: a model for weight gain with intensive insulin therapy. Am J Physiol Endocrinol Metab. 2013;304:E131–8.
   Google Scholar
• Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2011;13:1008–1019.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799–812.
   PubMed Web of Science ®Google Scholar
• Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27(Suppl3):13–20.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106–1118.
   PubMed Web of Science ®Google Scholar
• Chaggar PS, Shaw SM, Williams SG. Review article: thiazolidinediones and heart failure. Diab Vasc Dis Res. 2009;6:146–152.
   PubMed Web of Science ®Google Scholar
• Horita S, Nakamura M, Satoh N, et al. Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention. PPAR Res. 2015;2015:1–7.
   Web of Science ®Google Scholar
• Aubert RE, Herrera V, Chen W, et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12:716–721.
   PubMed Web of Science ®Google Scholar
• Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia. 2015;58:2238–2246.
   PubMed Web of Science ®Google Scholar
• Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS One. 2009;4:e6112.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf. 2004;27:841–856.
   PubMed Web of Science ®Google Scholar
• Actos (pioglitazone hydrochloride) prescribing information [online]. cited 2017 Jan. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf; http://www.actos.com/pi.pdf
   Google Scholar
• Avandia (rosiglitazone maleate) prescribing information [online] . cited 2017 Jan. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021071s034lbl.pdf; www.avandia.com
   Google Scholar
• Gaziano JM, Cincotta AH, O’Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33:1503–1508.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Cincotta AH, Vinik A, et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1:e002279.
   PubMed Web of Science ®Google Scholar
• Vinik AI, Cincotta AH, Scranton RE, et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18:931–943.
   PubMed Web of Science ®Google Scholar
• Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34:789–794.
   PubMed Web of Science ®Google Scholar
• Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154–1161.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH, Cincotta JM. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999;8:1683–1707.
   PubMedGoogle Scholar
• Scranton R, Cincotta A. Bromocriptine–unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11:269–279.
   PubMed Web of Science ®Google Scholar
• Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev. 2007;11:113–133.
   PubMed Web of Science ®Google Scholar
• Cincotta A. Hypothalamic role in the insulin resistance syndrome. In: Hansen B, Shaffrir E, eds. Resistance and Insulin Resistance Syndrome. London: Taylor and Francis; 2002. p. 271–312.
   Google Scholar
• Raskin P, Cincotta AH. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary. Expert Rev Endocrinol Metab. 2016;11:113–148.
   PubMed Web of Science ®Google Scholar
• Luo S, Ezrokhi M, Yang L, et al. Circdian dopamine activity at the biological clock regulates insulin sensitivity via the hypothalamus [abstract]. Diabetes. 2016;65(Suppl1):A489.
   Google Scholar
• Ezrokhi M, Luo S, Trubitsyna Y, et al. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol. 1993;264:E285–93.
   PubMed Web of Science ®Google Scholar
• Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000;71:68–78.
   PubMed Web of Science ®Google Scholar
• Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology. 1998;68:1–10.
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Meier A. Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport. 1997;8:3495–3499.
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Cincotta AH. Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. NeuroReport. 1999;10:2073–2077.
   PubMed Web of Science ®Google Scholar
• Luo M, Ezrokhi M, Trubitsyna Y, et al. Intrahypothalamic circuitry regulating hypothalamic fuel sensing to induce insulin sensitivity or insulin resistance [abstract]. Diabetologia. 2008;51(Suppl1):S59.
   Google Scholar
• Ezrokhi M, Luo S, Trubitsyna Y, et al. Weighted effects of bromocriptine treatment on glucose homeostasis during hyperglycemic versus euglycemic clamp conditions in insulin resistant hamsters: bromocriptine as a unique postprandial insulin sensitizer. J Diab Metab. 2012;S2:007.
   Google Scholar
• Moore MC, Smith M, Farmer B, et al. Timed daily bromocriptine mesylate (BC) administration improves glucose disposal in a canine diet-induced model of impaired glucose tolerance [abstract]. Diabetologia. 2014;57(Suppl1):S350.
   Google Scholar
• Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667–670.
   PubMed Web of Science ®Google Scholar
• Roe ED, Chamarthi B, Raskin P. Impact of bromocriptine-QR therapy on glycemic control and daily insulin requirement in type 2 diabetes mellitus subjects whose dysglycemia is poorly controlled on high-dose insulin: a pilot study. J Diabetes Res. 2015;2015:834903.
   PubMed Web of Science ®Google Scholar
• Florez H, Scranton R, Farwell WR, et al. Randomized clinical trial assessing the efficacy and safety of bromocriptine-qr when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. J Diabetes Metab. 2011;2:142.
   Google Scholar
• Luo S, Zhang Y, Ezrokhi M, et al. High-Fat feeding abolishes the insulin-sensitizing peak in circadian dopamine activity at the biological clock [abstract]. Diabetes. 2014;63(Suppl1):A470.
   Google Scholar
• Cincotta AH, Luo S, Zhang Y, et al. Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regulatory Integrative Comp. Physiol. 2000;278:R435–44.
   PubMed Web of Science ®Google Scholar
• Luo S, Luo J, Cincotta AH. Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology. 1999;70:460–465.
   PubMed Web of Science ®Google Scholar
• Zheng H, Liu X, Li Y, et al. Attenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetes. Am J Physiol Regul Integr Comp Physiol. 2014;306:R138–48.
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci. 2006;1083:129–152.
   PubMed Web of Science ®Google Scholar
• Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015;2015:341583.
   PubMed Web of Science ®Google Scholar
• Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome–causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126:159–172.
   PubMed Web of Science ®Google Scholar
• Chiodini I, Adda G, Scillitani A. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care. 2007;30:83–88.
   PubMed Web of Science ®Google Scholar
• Lam TK, Pocai A, Gutierrez-Juarez R, et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med. 2005;11:320–327.
   PubMed Web of Science ®Google Scholar
• Pocai A, Lam TK, Obici S, et al. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest. 2006;116:1081–1091.
   PubMed Web of Science ®Google Scholar
• Jordan SD, Könner AC, Brüning JC. Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis. Cell Mol Life Sci. 2010;67:3255–3273.
   PubMed Web of Science ®Google Scholar
• Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes Metab Res Rev. 2008;24:3–13.
   PubMed Web of Science ®Google Scholar
• Bell DSH. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine-QR. Postgradmed. 2012;124:121–135.
   PubMed Web of Science ®Google Scholar
• Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22:423–436.
   PubMed Web of Science ®Google Scholar
• Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12:144–153.
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100:899–904.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Postprandial dysmetabolism and the heart. Heart Fail Clin. 2012;8:563–573.
   PubMed Web of Science ®Google Scholar
• Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.
   PubMed Web of Science ®Google Scholar
• Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res. 2006;29:839–847.
   PubMed Web of Science ®Google Scholar
• Ezrokhi M, Trubitsyna Y, Luo S, et al. Timed dopamine agonist treatment ameliorates both vascular nitrosative/oxidative stress pathology and aortic stiffness in arteriosclerotic, hypertensive SHR rats [abstract]. Diabetes. 2010;59(Suppl1):A67.
   Google Scholar